Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INNO-235
- Development stage
- Preclinical
- Lead developer
- MindRank
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
INNO-235 is a preclinical, orally bioavailable, cereblon (CRBN)-based molecular glue degrader designed to concurrently induce proteasomal degradation of G1 to S phase transition 1 (GSPT1, also known as eRF3a) and casein kinase 1 alpha (CK1α), leading to potent antitumor activity in MYC-driven and TP53-mutant lymphomas, including Burkitt lymphoma.[3][5] By recruiting GSPT1 and CK1α to the CRBN E3 ubiquitin ligase complex, INNO-235 triggers integrated stress response (ISR) activation and both p53-dependent and p53-independent apoptosis, resulting in strong tumor growth inhibition in TP53-mutated Burkitt lymphoma models and offering a potential therapeutic strategy for MYC-driven malignancies with limited treatment options.[1][3][5]
Beyond the preview
Go deeper on INNO-235.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INNO-235.